Tenet Healthcare Corporation New THC

Tenet Healthcare is a Dallas-based healthcare services organization. It operates acute and specialty hospitals (50 as of December 2025) and hundreds of ambulatory surgery centers and other outpatient facilities across the US, primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

• Zacks Investment Research 2 oct

  Tenet Healthcare (THC) Outpaces Stock Market Gains: What You Should Know

  Tenet Healthcare stock rose 1.83% to $258.62, outperforming the S&P 500's 0.73% gain. The hospital operator is projected to report Q3 EPS of $4.59 (up 24.05% YoY) and revenue of $5.47 billion (up 3.4% YoY). For the full year, earnings are forecast at $21.04 per share and revenue at $22.2 billion. THC holds a Zacks Rank #3 (Hold) with a Forward P/E of 12.07 and PEG ratio of 0.97.

  

• Zacks Investment Research 30 sept

  Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

  Tenet Healthcare (THC) is accelerating share buybacks and raising 2026 free cash flow guidance to $1.825-$2.055 billion, supported by 27.1% year-over-year growth in operating cash flow to $2.2 billion. The company has $2.1 billion remaining in buyback authorization while continuing to invest in growth initiatives and managing debt obligations.

  

• Zacks Investment Research 30 sept

  Here's Why Tenet Healthcare (THC) is a Strong Growth Stock

  Tenet Healthcare (THC) is featured as a stock to watch with a #3 (Hold) Zacks Rank and an A VGM Score. The company shows strong growth prospects with forecasted year-over-year earnings growth of 25.4% for the current fiscal year, supported by three upward earnings estimate revisions in the last 60 days and an average earnings surprise of +22.7%.

  

• Zacks Investment Research 22 sept

  Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

  Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

  

• The Motley Fool 19 sept

  Tenet Healthcare Director Nadja West Sells 1,152 Shares

  Tenet Healthcare Director Nadja West sold 1,152 shares (5% of her direct holdings) on September 2, 2026, for approximately $298,138 at $258.80 per share. West retained 23,653 shares valued at $6.1 million, indicating continued confidence in the company. Analysts view the sale as routine profit-taking following strong 39% one-year stock performance.